Hemopurifier® to Aid Hep C Therapy in Compassionate-Use Program
December 10, 2012
Aethlon Medical Announces Initiation Of Compassionate-Use Program To Treat Hepatitis C Virus (HCV)
SAN DIEGO, Dec. 3, 2012 /PRNewswire/ – Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), will provide individuals who previously failed or subsequently relapsed standard-of-care drug regimens with treatment access to the Aethlon Hemopurifier®. The Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dosing, duration and tolerability of drug therapies.
Continue reading this entire article:
Food Coma's Impact on Those Battling Hepatitis C
Triple Drug Cocktail Can Defeat Hepatitis C with Cirrhosis